01426: Personalized Medicine for the Treatment of Canine Mast Cell Tumors
Grant Status: Closed
While surgery remains the mainstay of treatment for canine mast cell tumors (MCT), surgery alone is not curative in some cases, and not possible in other cases. Medical therapy remains an important component of MCT therapy. New drugs that affect signaling through the KIT growth factor receptor are showing considerable promise for the treatment of canine MCT, and MCT with mutations in the KIT protein that make it constantly active may be more sensitive to KIT inhibitors. The drug combination vinblastine and prednisone has roughly the same effectiveness as KIT inhibition against canine MCT; however, the two treatments have not been compared head-to-head, and it is not clear whether vinblastine or KIT inhibitors are more appropriate for the treatment of MCT without KIT mutations. We recently developed a rapid test, which can be performed on fine-needle aspirates, to determine whether MCT possess KIT mutations or not. We investigated the predictive value of KIT mutation status using this rapid genotyping assay, as well as KIT staining on biopsy sections, in dogs with measurable MCT randomized to receive either vinblastine or the KIT inhibitor toceranib (Palladia?). Randomization utilized a novel adaptive statistical strategy that makes use of the KIT assay results.
87 evaluable dogs were enrolled in this study at 4 participating study sites. 59 dogs were randomized to receive toceranib and 28 dogs were randomized to receive vinblastine. 5 dogs. remain on-study. Statistical analysis will take place when these dogs have been removed from study.
The results of this study will clarify whether KIT mutation testing is a useful decision-making tool for the selection of the best possible medical therapy for dogs with MCT.
Help Future Generations of Dogs
Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.